Cyxone AB (publ) (CYXO.ST)
SEK 0.02
(0.0%)
SEK 0.02
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -21.66 Million SEK | 48.95% |
| 2022 | -42.43 Million SEK | 5.79% |
| 2021 | -45.04 Million SEK | 8.07% |
| 2020 | -49 Million SEK | -39.34% |
| 2019 | -35.16 Million SEK | -127.84% |
| 2018 | -15.43 Million SEK | -74.92% |
| 2017 | -8.82 Million SEK | -112.22% |
| 2016 | -4.15 Million SEK | -2466.53% |
| 2015 | -162 Thousand SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -4.74 Million SEK | -2.18% |
| 2024 Q1 | -4.64 Million SEK | 21.35% |
| 2023 Q2 | -5.89 Million SEK | 1.14% |
| 2023 Q1 | -5.96 Million SEK | -184.18% |
| 2023 FY | -21.77 Million SEK | 48.7% |
| 2023 Q4 | -5.9 Million SEK | -13.77% |
| 2023 Q3 | -5.18 Million SEK | 12.04% |
| 2022 FY | -42.43 Million SEK | 5.79% |
| 2022 Q3 | -11.26 Million SEK | 11.33% |
| 2022 Q4 | -2.09 Million SEK | 81.36% |
| 2022 Q2 | -12.7 Million SEK | 23.84% |
| 2022 Q1 | -16.67 Million SEK | -19.12% |
| 2021 Q1 | -8.61 Million SEK | 28.36% |
| 2021 Q2 | -11.45 Million SEK | -33.05% |
| 2021 Q3 | -10.97 Million SEK | 4.22% |
| 2021 FY | -45.04 Million SEK | 8.07% |
| 2021 Q4 | -14 Million SEK | -27.59% |
| 2020 Q4 | -12.02 Million SEK | 4.65% |
| 2020 Q1 | -10.09 Million SEK | 50.52% |
| 2020 FY | -49 Million SEK | -39.34% |
| 2020 Q2 | -14.18 Million SEK | -40.53% |
| 2020 Q3 | -12.6 Million SEK | 11.13% |
| 2019 Q4 | -20.4 Million SEK | -258.36% |
| 2019 FY | -35.16 Million SEK | -127.84% |
| 2019 Q3 | -5.69 Million SEK | -31.24% |
| 2019 Q2 | -4.33 Million SEK | 8.9% |
| 2019 Q1 | -4.76 Million SEK | -4.78% |
| 2018 Q1 | -2.7 Million SEK | 16.66% |
| 2018 FY | -15.43 Million SEK | -74.92% |
| 2018 Q2 | -3.81 Million SEK | -40.9% |
| 2018 Q3 | -4.37 Million SEK | -14.8% |
| 2018 Q4 | -4.54 Million SEK | -3.9% |
| 2017 Q1 | -1.49 Million SEK | -14.87% |
| 2017 Q2 | -2.58 Million SEK | -73.04% |
| 2017 FY | -8.82 Million SEK | -112.22% |
| 2017 Q3 | -1.51 Million SEK | 41.36% |
| 2017 Q4 | -3.24 Million SEK | -114.44% |
| 2016 Q4 | -1.29 Million SEK | -5.19% |
| 2016 Q1 | -307 Thousand SEK | 0.0% |
| 2016 FY | -4.15 Million SEK | -2466.53% |
| 2016 Q2 | -1.15 Million SEK | -276.87% |
| 2016 Q3 | -1.23 Million SEK | -6.66% |
| 2015 FY | -162 Thousand SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 91.3% |
| Ziccum AB (publ) | -21.56 Million SEK | -0.468% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -32.071% |
| BioArctic AB (publ) | 252.64 Million SEK | 108.574% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -2463.432% |
| Mendus AB (publ) | -100.65 Million SEK | 78.479% |
| Genovis AB (publ.) | 54.22 Million SEK | 139.947% |
| Intervacc AB (publ) | -93.57 Million SEK | 76.853% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -39.64% |
| Active Biotech AB (publ) | -46.48 Million SEK | 53.401% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 220.279% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 60.913% |
| Aptahem AB (publ) | -10.1 Million SEK | -114.364% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 93.263% |
| Kancera AB (publ) | -65.04 Million SEK | 66.697% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 83.909% |
| Fluicell AB (publ) | -26.87 Million SEK | 19.413% |
| Saniona AB (publ) | -81.06 Million SEK | 73.279% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -75.095% |
| Biovica International AB (publ) | -126.07 Million SEK | 82.819% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 49.039% |
| AcouSort AB (publ) | -17.48 Million SEK | -23.869% |
| Xintela AB (publ) | -57.23 Million SEK | 62.156% |
| Abliva AB (publ) | -96.54 Million SEK | 77.565% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 93.331% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -518.003% |
| OncoZenge AB (publ) | -15.9 Million SEK | -36.216% |
| Amniotics AB (publ) | -29.07 Million SEK | 25.494% |
| 2cureX AB (publ) | -36.36 Million SEK | 40.431% |
| CombiGene AB (publ) | -36.3 Million SEK | 40.336% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -47.958% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 94.365% |
| Camurus AB (publ) | 532.35 Million SEK | 104.069% |
| Corline Biomedical AB | -1.78 Million SEK | -1111.465% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 88.017% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 48.034% |
| I-Tech AB | 24.43 Million SEK | 188.647% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 97.253% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 79.558% |
| Biosergen AB | -27.26 Million SEK | 20.554% |
| Cantargia AB (publ) | -290.01 Million SEK | 92.531% |
| NextCell Pharma AB | -43.17 Million SEK | 49.826% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 88.017% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -26.7% |
| Nanologica AB (publ) | -69.96 Million SEK | 69.039% |
| SynAct Pharma AB | -224.49 Million SEK | 90.351% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 50.967% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | 9.574% |
| LIDDS AB (publ) | -40.67 Million SEK | 46.745% |
| Lipum AB (publ) | -37.25 Million SEK | 41.856% |
| BioInvent International AB (publ) | -369.94 Million SEK | 94.145% |
| Alzinova AB (publ) | -16.52 Million SEK | -31.104% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 91.453% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -238.811% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 81.176% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -7.557% |
| Simris Alg AB (publ) | -36.63 Million SEK | 40.873% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 85.221% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 93.022% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 80.47% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -87.282% |